Delivery Order SPE2DB20D3103-SPE2DB25FP9L2
- Not listed
- The Defense Logistics Agency awarded a $1,219.46 delivery order to AmerisourceBergen Drug Corp for Mycophenolate 500 mg tablets (100 count) on July 21, 2025, with an ultimate completion date of July 22, 2025. This firm fixed price, competitively awarded contract—which includes no set-aside designation—represents a child order under AmerisourceBergen's larger pharmaceutical supply vehicle with DLA. The product will be performed at the contractor's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $2,743.68 to AmerisourceBergen Drug Corp for Mycophenolate 200 mg/ml suspension in 160 ml quantities. The contract, awarded July 22, 2025, with an ultimate completion date of July 23, 2025, represents a firm fixed-price delivery order with no set-aside designation. This award falls under a competitive procurement process, reflecting AmerisourceBergen's established capability to meet federal pharmaceutical supply requirements. The...
- This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract, valued at $1,379.40, is for the delivery of 4,564,886 units of the pharmaceutical drug Mycophenolate 500 mg tablets. The contract has a completion date of June 13, 2024 and is a firm fixed-price contract. Amerisourcebergen holds a larger $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
- The Defense Logistics Agency awarded a $4,296.65 delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Mycophenolate 200 mg/ml suspension in a 160 ml quantity, with completion targeted for July 28, 2025. This firm fixed price contract represents a non-competitive set-aside award to the pharmaceutical distributor's corporate office, with performance to be executed in Conshohocken, Pennsylvania, where the company maintains its headquarters. This delivery order...
- This is a delivery order issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Mycophenolate 500 mg tablets. The $2,563.60 Firm Fixed Price contract has a completion date of November 28, 2023. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to...
- This is a federal contract award by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Mycophenolate 500 mg tablets in 100-count packages, with a ceiling value of $1,127.04 and a period of performance through May 28, 2025. The contract is a delivery order with a firm fixed-price pricing type. It is not designated as a set-aside contract, indicating open competition....
- This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order with a Firm Fixed Price for the supply of 500-milligram Mycophenolate tablets. The award has a ceiling value of $3,005.76 and a completion date of June 9, 2025. This award is not set-aside and represents an open competition. AmerisourceBergen holds a substantial Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $2,662.25 to AmerisourceBergen Drug Corp for the supply of Mycophenolate 200 mg/mL suspension in 160 mL quantities. The contract, awarded on July 29, 2025, with a completion date of July 30, 2025, is structured as a firm fixed-price delivery order with no set-aside designation, indicating competitive award. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,438.04 firm fixed-price delivery order is for the supply of MYCOPHENOLATE 500 MG TABLET 500S, a pharmaceutical product. The contract has a performance period extending to July 11, 2025. AmerisourceBergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,713.68 contract is for the delivery of MYCOPHENOLATE 500 MG TABLET 500S, a pharmaceutical product, with a completion date of July 18, 2025. The contract is part of DLA's Medical Supply Chain program, which supports military and veteran healthcare systems. AmerisourceBergen Drug Corp holds a...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB25FP9L2Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Mycophenolate 500 mg tablets (500 count) valued at $1,676.36. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. The award was made through open competition with no set-aside designation, utilizing firm fixed pricing. The place of performance is listed as Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This procurement supports the Department of Defense's pharmaceutical supply chain requirements, with the ultimate completion date set for August 20, 2025. Mycophenolate is an immunosuppressant medication used in military and veteran healthcare systems, reflecting the broader scope of AmerisourceBergen's federal contract portfolio, which encompasses diabetes medications, neurological treatments, pain management pharmaceuticals, and specialized medical supplies. The company's substantial IDC vehicle with DLA demonstrates its established capability as a critical pharmaceutical distributor for military healthcare programs and positions it to serve additional customers including the Defense Health Agency and U.S. Coast Guard.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.7k | 8/19/25 |